Literature DB >> 28670368

Effect of ERβ-regulated ERK1/2 signaling on biological behaviors of prostate cancer cells.

Zhankui Zhao1, Honglian Yu2,3, Qingsheng Kong2,3, Chuanxin Liu3, Yanjun Tian3, Xiaoli Zeng3, Dandan Li3.   

Abstract

Estrogen receptor beta (ERβ) plays a role in prostate carcinogenesis. In this study, we investigated the effects of ERβ gene silencing in PC3 androgen-independent prostate cancer cells. PC3 cells were transfected with vector alone, scrambled shRNA vector, vector encoding ERβ-targeting shRNA (shERβ), or shERβ followed by addition of PD98059, a mitogen-activated protein kinase kinase (MEK) inhibitor (shERβ+PD98059). Cyclin D1, Bcl-2, matrix metalloproteinase (MMP)2, and phosphorylated (p-) extracellular signal-regulated kinase (ERK1/2) expression was detected by western blotting. While ERK1/2 expression was comparable in all cells, p-ERK1/2 expression was highest in shERβ cells, and lowest in shERβ+PD98059 cells. Bcl-2, cyclin D1, and MMP2 expression was highest and lowest in shERβ and shERβ+PD98059 cells, respectively. Flow cytometry analysis showed that ERβ silencing promoted cell proliferation by decreasing the percentage of cells in G0/G1. Analysis of colony formation, migration, and invasion capacities, measured using soft agar colony-formation, wound-healing, and transwell invasion assays, respectively, showed that ERβ silencing augments cell proliferation, migration, and invasion, and that this increase is reversed by PD98059 treatment. A tumor xenograft model in nude mice was used to assess the effect of ERβ silencing on the biological behavior of PC3 cells. Colony formation assays and tumor transplantation data indicated that ERβ silencing promotes tumor formation. Immunohistochemical analysis of tumors showed that vascular endothelial growth factor (VEGF) and p-ERK1/2 expression, but not that of total ERK1/2, was increased upon ERβ silencing. In conclusion, out data demonstrate that ERβ gene silencing enhances malignant biological behaviors of PC3 cells by activating the ERK1/2 signaling pathway.

Entities:  

Keywords:  ERK1/2; Estrogen receptor beta; apoptosis; proliferation; prostate cancer

Year:  2017        PMID: 28670368      PMCID: PMC5489880     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  36 in total

Review 1.  How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?

Authors:  Jerry E Chipuk; Douglas R Green
Journal:  Trends Cell Biol       Date:  2008-03-07       Impact factor: 20.808

Review 2.  ERK implication in cell cycle regulation.

Authors:  Jean-Claude Chambard; Renaud Lefloch; Jacques Pouysségur; Philippe Lenormand
Journal:  Biochim Biophys Acta       Date:  2006-11-17

3.  Apoptotic effect of demethoxyfumitremorgin C from marine fungus Aspergillus fumigatus on PC3 human prostate cancer cells.

Authors:  Young-Sang Kim; Se-Kwon Kim; Sun Joo Park
Journal:  Chem Biol Interact       Date:  2017-03-28       Impact factor: 5.192

Review 4.  How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?

Authors:  Yohannes Mebratu; Yohannes Tesfaigzi
Journal:  Cell Cycle       Date:  2009-04-11       Impact factor: 4.534

5.  Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.

Authors:  Chiachen Chen; Yuan-Ching Chang; Michael S Lan; Mary Breslin
Journal:  Int J Oncol       Date:  2013-01-23       Impact factor: 5.650

6.  Expression of estrogen receptor-B ( ER-B ) in bengin and malignant prostatic epithelial cells and its correlation with the clinico-pathological features.

Authors:  Samia M Gabal; Fahima M Habib; Dina O Helmy; Mohammad F Ibrahim
Journal:  J Egypt Natl Canc Inst       Date:  2007-12

Review 7.  Modulatory actions of neuropeptide Y on prostate cancer growth: role of MAP kinase/ERK 1/2 activation.

Authors:  Massimiliano Ruscica; Elena Dozio; Marcella Motta; Paolo Magni
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

Review 8.  Targeting the Bcl-2 family for cancer therapy.

Authors:  Shibu Thomas; Bridget A Quinn; Swadesh K Das; Rupesh Dash; Luni Emdad; Santanu Dasgupta; Xiang-Yang Wang; Paul Dent; John C Reed; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Ther Targets       Date:  2012-11-22       Impact factor: 6.902

9.  Estrogen receptor β promoter methylation: a potential indicator of malignant changes in breast cancer.

Authors:  Lei Gao; Xiaolong Qi; Kaiwen Hu; Ruili Zhu; Wei Xu; Shipeng Sun; Lixin Zhang; Ximing Yang; Baojin Hua; Guijian Liu
Journal:  Arch Med Sci       Date:  2016-02-02       Impact factor: 3.318

Review 10.  Oestrogens and oestrogen receptors in prostate cancer.

Authors:  Karolina Kowalska; Agnieszka Wanda Piastowska-Ciesielska
Journal:  Springerplus       Date:  2016-04-26
View more
  4 in total

1.  Communication between genomic and non-genomic signaling events coordinate steroid hormone actions.

Authors:  Sandi R Wilkenfeld; Chenchu Lin; Daniel E Frigo
Journal:  Steroids       Date:  2017-11-16       Impact factor: 2.668

2.  Antitumor effects of aconitine in A2780 cells via estrogen receptor β‑mediated apoptosis, DNA damage and migration.

Authors:  Xiuying Wang; Yuanyuan Lin; Yi Zheng
Journal:  Mol Med Rep       Date:  2020-07-10       Impact factor: 2.952

Review 3.  Signal Crosstalk and the Role of Estrogen Receptor beta (ERβ) in Prostate Cancer.

Authors:  Jialin Li; Quanliang Liu; Chengming Jiang
Journal:  Med Sci Monit       Date:  2022-04-06

4.  IRS-2 deubiquitination by USP9X maintains anchorage-independent cell growth via Erk1/2 activation in prostate carcinoma cell line.

Authors:  Haruka Furuta; Hidehito Yoshihara; Toshiaki Fukushima; Yosuke Yoneyama; Akihiro Ito; Claire Worrall; Ada Girnita; Leonard Girnita; Minoru Yoshida; Tomoichiro Asano; Masayuki Komada; Naoyuki Kataoka; Kazuhiro Chida; Fumihiko Hakuno; Shin-Ichiro Takahashi
Journal:  Oncotarget       Date:  2018-09-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.